Fitbit’s latest earnings call was a mixed bag for the wearable giant. The company’s revenue and device sales were up; however, the average price of the devices was down. This has led to the company to lower its revenue guidance by $95 million.
It appears to be continuing to focus in on its health division, which is seeing an uptick in year-over-year revenue, and is on track to meet its $100...
Teladoc Health stuck to its game plan in the second quarter and first half of 2019, the company reported last week in its earnings call.
Total revenue, membership and service utilization are each trending upward while the telehealth company’s international and strategic investments appear to be taking hold. However, the company still has yet to turn a profit, although it is aiming to be cash flow...
Digital health-focused moves from payers throughout the last quarter ranged from partnership agreements and program launches to acquisitions and CMS coverage rulings. Several such headlines came from major players like Cigna, UnitedHealth Group, pharmacy benefit managers (PBMs) and various Blue Cross plans, and frequently involved digital health mainstays such as Livongo, Fitbit, Doctor on Demand...
Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the company shared during an investor’s call this morning.
Specifically, the company highlighted a 72.9% increase in organic sales growth during the three-month period, reaching a worldwide total sales...
The first half of 2019 has been bigger for digital health than any year opening before it, according to a new funding report from Mercom Capital Group.
While these conclusions were similar to those of MobiHealthNews and Rock Health, both released earlier this month, Mercom’s count pegged 2019’s to-date funding a bit higher at $5.1 billion raised through 318 deals (2018 saw $4.9 billion from 383...
Diving deeper into digital, this quarter the pharma giants have continued to implement new tools to enhance clinical trials, support medication management with technology and partner in developing digital therapeutics.
Onc, a foreign entity to this established industry, pharma executives are now becoming better versed in working with digital health companies and sharing the lessons they've...
